Roth Capital lowered the firm’s price target on Cingulate (CING) to $14 from $16 and keeps a Buy rating on the shares. The company’s new drug application for CTx-1301 in attention-deficit/hyperactivity disorder is awaiting FDA decision with a May 31 action date, the analyst tells investors in a research note. The firm updated Cingulate’s model to reflect the Q4 results.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CING:
- Cingulate files to sell 3.5M shares of common stock for holders
- PolyPid Approaches NDA Submission as New Medicare Model Creates Strong Incentives for SSI Prevention
- Cingulate announces U.S. patent notice of allowance
- Cingulate reports Q4 net loss $6.3M vs. $6.2M last year
- Cingulate sees cash runway into late 4Q26